QuidelOrtho CorpQDELEarnings & Financial Report
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
QDEL Q1 FY2027 Key Financial Metrics
Revenue
$619.8M
Gross Profit
N/A
Operating Profit
N/A
Net Profit
$-91.8M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
-14.8%
YoY Growth
-10.5%
EPS
$-1.35
QuidelOrtho Corp Q1 FY2027 Financial Summary
QuidelOrtho Corp reported revenue of $619.8M (down 10.5% YoY) for Q1 FY2027, with a net profit of $-91.8M (-14.8% margin).
Key Financial Metrics
| Total Revenue | $619.8M |
|---|---|
| Net Profit | $-91.8M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q1 FY2027 |
Revenue Breakdown
QuidelOrtho Corp Q1 FY2027 revenue of $619.8M breaks down across 4 segments, led by Labs at $353.1M (57.0% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Labs | $353.1M | 57.0% |
| Immunohematology | $138.3M | 22.3% |
| Point of Care | $112.8M | 18.2% |
| Molecular Diagnostics | $7.8M | 1.3% |
QuidelOrtho Corp Revenue by Segment — Quarterly Trend
QuidelOrtho Corp revenue by segment across the last 4 reported quarters, showing how each business line (such as Labs and Immunohematology) has evolved quarter over quarter.
| Segment | Q1 FY2027 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Labs | $353.1M | $373.8M | $369.7M | $373.1M |
| Immunohematology | $138.3M | $142.0M | $132.3M | $128.5M |
| Point of Care | $112.8M | — | — | — |
| Molecular Diagnostics | $7.8M | $4.8M | $5.6M | $7.6M |
QuidelOrtho Corp Annual Revenue by Year
QuidelOrtho Corp annual revenue history includes year-by-year totals (for example, 2024 revenue was $2.8B).
QuidelOrtho Corp Quarterly Revenue & Net Profit History
QuidelOrtho Corp results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2027 | $619.8M | -10.5% | $-91.8M | -14.8% |
| Q3 FY2025 | $699.9M | -3.7% | $-733.0M | -104.7% |
| Q2 FY2025 | $613.9M | -3.6% | $-255.4M | -41.6% |
| Q1 FY2025 | $692.8M | -2.6% | $-12.7M | -1.8% |
| Q4 FY2024 | $707.8M | -4.7% | $-178.4M | -25.2% |
| Q3 FY2024 | $727.1M | -2.3% | $-19.9M | -2.7% |
| Q2 FY2024 | $637.0M | -4.2% | $-147.7M | -23.2% |
| Q1 FY2024 | $711.0M | -16.0% | $-1.7B | -239.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q1 2027 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $711.0M | $637.0M | $727.1M | $707.8M | $692.8M | $613.9M | $699.9M | $619.8M |
| YoY Growth | -16.0% | -4.2% | -2.3% | -4.7% | -2.6% | -3.6% | -3.7% | -10.5% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q1 2027 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $6.70B | $6.69B | $6.80B | $6.42B | $6.46B | $6.38B | $5.68B | $5.63B |
| Liabilities | $3.40B | $3.52B | $3.61B | $3.44B | $3.46B | $3.59B | $3.64B | $3.78B |
| Equity | $3.31B | $3.17B | $3.19B | $2.98B | $3.00B | $2.79B | $2.04B | $1.85B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-700000 | $-97.9M | $117.9M | $63.7M | $65.6M | $-46.8M | $-45.5M |